Worth reading
66In focus
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
3780000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Exercise status report for the 17th Series Stock Acquisition Rights issued through a third-party allotment with exercise price adjustment clauses
発行・処分する株式数
3,780,000 new shares; 0 treasury shares transferred
Intended allottee
EVO FUND (allottee of the previously issued stock acquisition rights)
Existing Shares and Increase
+4.90%Rate of increase
92,354,098 shares96,134,098Shares
4.9% (exercise ratio subject to the exercise restrictions; the shares exercised in this transaction represent approximately 4.1% of the number of issued shares)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
Subject to exercise price adjustment clauses. The exercise price in April 2026 was ¥53.0–¥59.0 per share, depending on the exercise date; details of the adjustment clauses and the floor price were not disclosed.
Number of Stock Acquisition Rights
Total issued: 192,000 rights; unexercised balance: 0 rights
Procedures under the Corporate Code of Conduct
Describes compliance with the exercise restrictions under Article 434 of the Listing Regulations. The number of shares delivered across all series was 3,780,000, the number of listed shares as of the payment date for the issuance was 76,933,798, and the exercise ratio subject to the exercise restrictions was 4.9%.
Most recent equity financing
25 August 2025: Issuance of the 17th Series Stock Acquisition Rights with exercise price adjustment clauses, with EVO FUND as the allottee. Amount: not disclosed
| Item | Details |
|---|---|
| Type of issuance or disposal | Exercise status report for the 17th Series Stock Acquisition Rights issued through a third-party allotment with exercise price adjustment clauses |
| Number of shares to be issued or disposed of | 3,780,000 new shares; 0 treasury shares transferred |
| Intended allottee | EVO FUND (allottee of the previously issued stock acquisition rights) |
| Dilution Rate | 4.9% (exercise ratio subject to the exercise restrictions; the shares exercised in this transaction represent approximately 4.1% of the number of issued shares) |
| Total number of issued shares | 92,354,098 shares (as of the end of the month preceding the subject month) → 96,134,098 shares (calculated after exercise) |
| Exercise price | Subject to exercise price adjustment clauses. The exercise price in April 2026 was ¥53.0–¥59.0 per share, depending on the exercise date; details of the adjustment clauses and the floor price were not disclosed. |
| Number of Stock Acquisition Rights | Total issued: 192,000 rights; unexercised balance: 0 rights |
| Procedures under the Corporate Code of Conduct | Describes compliance with the exercise restrictions under Article 434 of the Listing Regulations. The number of shares delivered across all series was 3,780,000, the number of listed shares as of the payment date for the issuance was 76,933,798, and the exercise ratio subject to the exercise restrictions was 4.9%. |
| Most recent equity financing | 25 August 2025: Issuance of the 17th Series Stock Acquisition Rights with exercise price adjustment clauses, with EVO FUND as the allottee. Amount: not disclosed |
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly exercise status for April 2026 and the completion of exercise of all of these stock acquisition rights.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.